LivaNova PLC (NASDAQ:LIVN) Receives $74.11 Consensus PT from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $74.7778.

LIVN has been the subject of a number of analyst reports. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a research note on Tuesday, December 16th. Mizuho boosted their price target on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Needham & Company LLC upped their price target on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Finally, Barclays boosted their target price on shares of LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th.

Institutional Trading of LivaNova

A number of institutional investors have recently bought and sold shares of LIVN. Hantz Financial Services Inc. grew its holdings in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares during the last quarter. State of Wyoming bought a new stake in shares of LivaNova during the 2nd quarter worth $31,000. Quarry LP acquired a new position in LivaNova in the 3rd quarter valued at $36,000. EverSource Wealth Advisors LLC raised its holdings in LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the period. Finally, Covestor Ltd raised its holdings in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after acquiring an additional 392 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

LIVN opened at $65.26 on Thursday. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29. The business’s 50 day moving average is $65.03 and its 200-day moving average is $59.40. The stock has a market cap of $3.57 billion, a PE ratio of -14.63 and a beta of 0.92. LivaNova has a twelve month low of $32.48 and a twelve month high of $71.92.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. The company had revenue of $360.86 million for the quarter, compared to analyst estimates of $354.31 million. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period last year, the company earned $0.81 earnings per share. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, analysts predict that LivaNova will post 2.85 earnings per share for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.